Log in

NASDAQ:ITCI - Intra-Cellular Therapies Stock Price, Forecast & News

$12.82
+0.32 (+2.56 %)
(As of 12/15/2019 10:08 AM ET)
Today's Range
$12.45
Now: $12.83
$13.09
50-Day Range
$8.63
MA: $9.74
$12.83
52-Week Range
$6.75
Now: $12.83
$15.00
Volume2.04 million shs
Average Volume1.11 million shs
Market Capitalization$708.71 million
P/E RatioN/A
Dividend YieldN/A
Beta1.21
Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disorders. The company is developing its lead drug candidate, lumateperone for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ITCI
CUSIPN/A
Phone646-440-9333

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$250,000.00
Book Value$5.81 per share

Profitability

Net Income$-155,130,000.00

Miscellaneous

Employees73
Market Cap$708.71 million
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable

Receive ITCI News and Ratings via Email

Sign-up to receive the latest news and ratings for ITCI and its competitors with MarketBeat's FREE daily newsletter.


Intra-Cellular Therapies (NASDAQ:ITCI) Frequently Asked Questions

What is Intra-Cellular Therapies' stock symbol?

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

How were Intra-Cellular Therapies' earnings last quarter?

Intra-Cellular Therapies Inc (NASDAQ:ITCI) posted its quarterly earnings data on Tuesday, November, 5th. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.80) by $0.17. View Intra-Cellular Therapies' Earnings History.

When is Intra-Cellular Therapies' next earnings date?

Intra-Cellular Therapies is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Intra-Cellular Therapies.

What price target have analysts set for ITCI?

6 brokerages have issued twelve-month target prices for Intra-Cellular Therapies' shares. Their forecasts range from $16.00 to $28.00. On average, they expect Intra-Cellular Therapies' share price to reach $23.60 in the next twelve months. This suggests a possible upside of 84.0% from the stock's current price. View Analyst Price Targets for Intra-Cellular Therapies.

What is the consensus analysts' recommendation for Intra-Cellular Therapies?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intra-Cellular Therapies.

What are Wall Street analysts saying about Intra-Cellular Therapies stock?

Here are some recent quotes from research analysts about Intra-Cellular Therapies stock:
  • 1. According to Zacks Investment Research, "Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York. " (10/24/2019)
  • 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $26 price target on ITCI shares. Intra-Cellular reported 1Q19 financial performance, ending the period with cash of $312.8M. Our model projects sufficient funding into 2H20 and through several clinical and regulatory milestones including NDA acceptance/approval of lumateperone for schizophrenia and P3 data in bipolar depression (Studies 401 & 404) that are expected later this quarter. We also look forward to luma’s potential approval in 3Q19, the establishment of the company’s commercial team and its market launch as a differentiated, broadly active neuropsych product." (5/8/2019)

Has Intra-Cellular Therapies been receiving favorable news coverage?

Media stories about ITCI stock have been trending negative recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Intra-Cellular Therapies earned a media sentiment score of -2.7 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Intra-Cellular Therapies.

Are investors shorting Intra-Cellular Therapies?

Intra-Cellular Therapies saw a increase in short interest in the month of November. As of November 29th, there was short interest totalling 10,800,000 shares, an increase of 9.1% from the November 14th total of 9,900,000 shares. Based on an average daily volume of 959,400 shares, the days-to-cover ratio is currently 11.3 days. Currently, 23.2% of the shares of the stock are short sold. View Intra-Cellular Therapies' Current Options Chain.

Who are some of Intra-Cellular Therapies' key competitors?

What other stocks do shareholders of Intra-Cellular Therapies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Synergy Pharmaceuticals (SGYP), Celgene (CELG), Zynerba Pharmaceuticals (ZYNE), ACADIA Pharmaceuticals (ACAD), Gilead Sciences (GILD), Crispr Therapeutics (CRSP), Flexion Therapeutics (FLXN), Sarepta Therapeutics (SRPT), AbbVie (ABBV) and Amarin (AMRN).

Who are Intra-Cellular Therapies' key executives?

Intra-Cellular Therapies' management team includes the folowing people:
  • Dr. Sharon Mates, Co-Founder, Chairman, CEO & Pres (Age 66)
  • Mr. Lawrence J. Hineline CPA, Sr. VP of Fin., CFO, Treasurer and Assistant Sec. (Age 63)
  • Dr. Robert E. Davis, Sr. VP & Chief Scientific Officer (Age 68)
  • Mr. Michael I. Halstead J.D., Exec. VP, Gen. Counsel, Corp. Compliance Officer & Sec. (Age 46)
  • Dr. Andrew Satlin M.D., Exec. VP & Chief Medical Officer (Age 64)

Who are Intra-Cellular Therapies' major shareholders?

Intra-Cellular Therapies' stock is owned by many different of retail and institutional investors. Top institutional investors include State Street Corp (2.09%), Rhenman & Partners Asset Management AB (1.54%), Point72 Asset Management L.P. (1.01%), General American Investors Co. Inc. (0.62%), Squarepoint Ops LLC (0.27%) and Pictet Asset Management Ltd. (0.26%). Company insiders that own Intra-Cellular Therapies stock include Christopher D Alafi, Joel S Marcus, Kimberly E Vanover, Lawrence J Hineline, Mark Neumann, Michael Halstead, Robert E Davis and Sharon Mates. View Institutional Ownership Trends for Intra-Cellular Therapies.

Which major investors are selling Intra-Cellular Therapies stock?

ITCI stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Barclays PLC and Stifel Financial Corp. Company insiders that have sold Intra-Cellular Therapies company stock in the last year include Kimberly E Vanover, Lawrence J Hineline, Mark Neumann, Michael Halstead and Sharon Mates. View Insider Buying and Selling for Intra-Cellular Therapies.

Which major investors are buying Intra-Cellular Therapies stock?

ITCI stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., State Street Corp, Squarepoint Ops LLC, General American Investors Co. Inc., Public Employees Retirement System of Ohio, Voloridge Investment Management LLC, Russell Investments Group Ltd. and California Public Employees Retirement System. View Insider Buying and Selling for Intra-Cellular Therapies.

How do I buy shares of Intra-Cellular Therapies?

Shares of ITCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Intra-Cellular Therapies' stock price today?

One share of ITCI stock can currently be purchased for approximately $12.83.

How big of a company is Intra-Cellular Therapies?

Intra-Cellular Therapies has a market capitalization of $708.71 million and generates $250,000.00 in revenue each year. The biopharmaceutical company earns $-155,130,000.00 in net income (profit) each year or ($2.84) on an earnings per share basis. Intra-Cellular Therapies employs 73 workers across the globe.View Additional Information About Intra-Cellular Therapies.

What is Intra-Cellular Therapies' official website?

The official website for Intra-Cellular Therapies is http://www.intracellulartherapies.com/.

How can I contact Intra-Cellular Therapies?

Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 646-440-9333 or via email at [email protected]


MarketBeat Community Rating for Intra-Cellular Therapies (NASDAQ ITCI)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  406 (Vote Outperform)
Underperform Votes:  335 (Vote Underperform)
Total Votes:  741
MarketBeat's community ratings are surveys of what our community members think about Intra-Cellular Therapies and other stocks. Vote "Outperform" if you believe ITCI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ITCI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel